Prana Updates Progress on PBT2 Trials
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Prana Alzheimers disease Development Program update
- Appendix 4D Half Yearly Report and Accounts
- Appendix 4E and Annual Report 2015
- Trial presented at World Congress on Huntington`s Disease
- Share Purchase Plan 2013 Offer Document
Later from Alterity Therapeutics
- New benchmark test to assess HD patients in clincial trials
- New York Academy of Sciences Symposium Discusses PBT2
- Prana announces $5.8 million R&D refund
- Prana Announces Successful A$7 milion Capital Raising
- Prana Completes Phase 2 Huntington Disease Trial with PBT2
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics